Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Trial Details

NCT ID
NCT07427394
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Camizestrant
  • Atirmociclib
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789
  • East Providence, Rhode Island, United States|41.81371,-71.37005
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Cambridge, United Kingdom|52.2,0.11667
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Participants with advanced adenocarcinoma of the breast and must have received prior adequate therapy in accordance with local practice for their t…
  • Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to…
  • Eastern cooperative oncology group (ECOG)/World Health Organization (WHO) performance status 0 to 1, and a minimum life expectancy of 12 weeks.
  • At least one lesion that is measurable and/or non-measurable, as per RECIST 1.1 and that can be accurately assessed at baseline and is suitable for…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →